Linked Life Data

15852202

Source:http://linkedlifedata.com/resource/pubmed/id/15852202

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2005-4-26
pubmed:abstractText
The possible association of estrogen (E) with or without progestin (P) and breast cancer has been addressed in many studies for several decades. The recent reported prospective double-blind Women's Health Initiative (WHI) study suggests that E + P increases the risk of breast cancer if a woman is an average of 63 years old when she begins replacement therapy. One third of the patients in this study were 70 to 79 years of age when E + P was begun--obviously several decades past menopausal. Retrospective and observational studies suggest protection or no increased risk. The WHI-E only study actually notes a 23% reduction in breast cancer compared with the placebo. It would appear from a review of the literature that if there is an increased risk for breast cancer with E or E + P, it is minimal.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1526-8004
pubmed:author
pubmed:issnType
Print
pubmed:volume
23
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
167-71
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Breast cancer: the role of hormone therapy.
pubmed:affiliation
Department of Obstetrics and Gynecology, University Midlife Women's Health, Medical University of South Carolina, 1280 Johnnie Dodds Boulevard, Mt. Pleasant, SC 29464, USA. creasman@musc.edu
pubmed:publicationType
Journal Article, Review